SCI Abstract

search
+
Gepotidacin: First Approval
Gepotidacin: First Approval
Gepotidacin (BLUJEPA), a small molecule triazaacenaphthylene bacterial type II topoisomerase inhibitor (BTI) antibacterial...
Nipocalimab: First Approval
Nipocalimab: First Approval
Nipocalimab (nipocalimab-aahu; IMAAVY™) is a fully human monoclonal antibody that binds to and blocks the neonatal f...
Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management
Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management
Insulin icodec (icodec) is a first-in-class once-weekly basal insulin approved for the treatment of adults with type 1 dia...
PCSK9 Inhibitors: A Potential Priority Choice for Lipid Management in Patients with Diabetic Kidney Disease
PCSK9 Inhibitors: A Potential Priority Choice for Lipid Management in Patients with Diabetic Kidney Disease
Diabetic kidney disease (DKD), a severe microvascular complication of diabetes mellitus (DM), is the predominant cause of ...
Managing Burning Mouth Syndrome: Current and Future Directions
Managing Burning Mouth Syndrome: Current and Future Directions
Burning mouth syndrome (BMS) is a chronic pain condition characterized by a persistent burning sensation in the oral mucos...
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy
Measurable (or minimal) residual disease (MRD) testing offers critical prognostic insight in multiple myeloma (MM), surpas...
Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review
Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review
Our objective was to systematically synthesize and evaluate the existing evidence from meta-syntheses (systematic reviews ...
Update on Medical Treatment of Cushing’s Syndrome
Update on Medical Treatment of Cushing’s Syndrome
First-line treatment of endogenous Cushing’s syndrome (CS) is surgical removal of the tumor responsible for cortisol...
The Road to Remyelination in Multiple Sclerosis: Breakthroughs, Challenges, and Considerations for Future Trial Design
The Road to Remyelination in Multiple Sclerosis: Breakthroughs, Challenges, and Considerations for Future Trial Design
Despite major advances in multiple sclerosis (MS) treatment, disability accumulation independent of relapse activity remai...
Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition
Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition
Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra-rare acquired genetic stem cell disorder based on a mutation in the...
Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight
Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight
The incidence of gastroesophageal cancers is rising, driven, in part, by an increasing burden of risk factors of obesity a...
Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis
Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis
Neurotrophic keratitis is a rare eye condition characterised by reduced or absent corneal sensation. This leads to impaire...
Antibacterials with Novel Chemical Scaffolds in Clinical Development
Antibacterials with Novel Chemical Scaffolds in Clinical Development
The rise of antimicrobial resistance represents a significant global health threat, driven by the diminishing efficacy of ...
Emerging Immunotherapies for Disease Modification of Type 1 Diabetes
Emerging Immunotherapies for Disease Modification of Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is characterized by the progressive, autoimmune-mediated destruction of β cells. As s...
Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits
Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits
Buprenorphine is an agonist at the mu opioid receptor (MOR) and antagonist at the kappa (KOR) and delta (DOR) receptors an...
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology
Due to the lack of a comprehensive pharmacology test set, evaluating the potential and value of large language models (LLM...
Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review
Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review
Tuberculosis (TB) is the leading cause of death from a single infectious agent. The burden is highest in some low- and mid...
Inavolisib: First Approval
Inavolisib: First Approval
Inavolisib (Itovebi™) is an orally administered, phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor being de...
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have revolutionized the treatment of hormone-receptor positive (HR+), HER...
Marstacimab: First Approval
Marstacimab: First Approval
Marstacimab (marstacimab-hncq; HYMPAVZI™) is a subcutaneously administered human monoclonal immunoglobulin G1 antibo...
The Future of Microbiome Therapeutics
The Future of Microbiome Therapeutics
The human microbiome exerts profound influence over various biological processes within the body. Unlike many host determi...
Ebronucimab: First Approval
Ebronucimab: First Approval
Ebronucimab (伊喜宁®) is a subcutaneous fully human anti-proprotein convertase subtilisin/kexin typ...
Correction: Tegileridine: First Approval
Correction: Tegileridine: First Approval
Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a sh...
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses
Although paracetamol (acetaminophen) combined with other analgesics can reduce pain intensity in some pain conditions, its...
Tunlametinib: First Approval
Tunlametinib: First Approval
Tunlametinib (科露平®) is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK ...
Zolbetuximab: First Approval
Zolbetuximab: First Approval
Zolbetuximab (VYLOY™), a recombinant, chimeric, anti-claudin 18.2 (CLDN18.2) monoclonal antibody (mAb), is being dev...
Mavorixafor: First Approval
Mavorixafor: First Approval
Mavorixafor (XOLREMDI™) is an oral, selective C-X-C chemokine receptor 4 (CXCR4) antagonist developed by X4 Pharmace...
Bone Fragility in Diabetes and its Management: A Narrative Review
Bone Fragility in Diabetes and its Management: A Narrative Review
Bone fragility is a serious yet under-recognised complication of diabetes mellitus (DM) that is associated with significan...
Elafibranor: First Approval
Elafibranor: First Approval
Elafibranor (IQIRVO®) is a first-in-class peroxisome proliferator-activated receptor (PPAR) agonist being developed b...
Anticoagulation in Chronic Kidney Disease
Anticoagulation in Chronic Kidney Disease
The nuanced landscape of anticoagulation therapy in patients with chronic kidney disease (CKD) presents a formidable chall...
Load More
format_indent_increase